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Abstract
Background: Structural rearrangements of chromosome 19p13.3 are a rare condition, and their phenotypic
consequences remain not well defined, because of the variability of clinical manifestations. Increasing knowledge
of new 19p13.3 microdeletion is useful to clarify the phenotypic variability observed in some patients. In a small
number of recent papers, patients with intellectual disabilities, multiple congenital anomalies and microdeletion
of the chromosome band 19p13.3 have been described. However, little is known about genes responsible for
clinical features in patients carriers of 19p13.3 microdeletion; thus, increasing number of reported cases will be
helpful to investigate the contribution of candidate genes, providing bases for future investigations.
Case Presentation: Here, we report on a 10-years-old girl referred to our genetics clinic due to intellectual
disability, attention deficit, behavioral and speech delay, hypotonia, facial dysmorphisms, eye anomalies and
congenital malformations. Using an high resolution SNP array, we identified a de novo microdeletion of
chromosome 19p13.3, resulting in the heterozygous loss of 27 RefSeq genes and a miRNA, partially overlapping
with three others deletions already reported in literature, but extending downstream (centromeric) for additional
386 Kb. This chromosomal region includes 13 genes amongst of which we suggest for the first time the APC2, PLK5
and MBD3 genes as potential functional candidates for neurodevelopmental and behavioral phenotypes observed.
Conclusions: Here we describe a patient with a 19p13.3 microdeletion that spans to the downstream chromosomal
region with respect to the overlapping deletions previously reported in several other cases. The neurobehavioral
features observed in our case has extended the phenotypic spectrum associated with the 19p13.3 microdeletion.
New candidate genes are proposed for the neurobehavioral phenotype observed in our case.
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Background
Copy number variations (CNVs) are recognized as
consisting genetic causes or susceptibility factors for
neurodevelopmental disorders (NDDs), dysmorphic syn-
dromes and multiple congenital anomalies (MCAs).
CNVs can arise on all chromosomes, and their clinical
manifestations depends on gene content, on the involve-
ment of imprinted regions and on the nature of the re-
arrangement; furthermore, the variety of phenotypes
may be due to several factors such as incomplete pene-
trance, variable expressivity and environmental factors.
Chromosome 19 has the highest gene density, indicating
its importance in several biological function [1] and,
therefore, even small aberrations on this chromosome
are likely to have clinical consequences. To date, with
the widespread use of genome wide microarray technol-
ogy, several cases of interstitial 19p13.3 microdeletion
have been reported, and the increasing resolution of ana-
lysis methods allowed the improvement of genotype-
phenotype correlations. These observations highlighted
both common clinical features and phenotype variations
among described patients, probably due to different size
of the deletions and their gene content.
Moreover, some papers started to describe patients
with intellectual disabilities (IDs) and MCAs associated
with 19p13.3 microdeletions [2, 3], highlighting the
evidence that 19p13.3 microdeletion may cause these
clinical conditions. In order to deeply investigate the
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phenotype associated with 19p13.3 microdeletion, we
describe the clinical and molecular data of a patient car-
rier of a 0.71 Mb de novo interstitial microdeletion of
chromosome 19p13.3. Interestingly, the deletion identi-
fied in our patient partially overlap with those already
reported in literature, and extend towards the proximal
(centromeric) end for further 386 Kb. This region in-
cludes 13 genes and a miRNA, some of them seems to




The patient described herein, a 10-year-old girl, is the
first child of healthy non-consanguineous parents, born
after an uneventful pregnancy affected by ID, attention
deficit, behavioral and speech delay, hypotonia, facial
dysmorphisms, eye anomalies. She also showed congeni-
tal malformations such as cerebral anomaly and forward
anus. Her birth weight was 3,450 g (50th centile), length
was 50,7 cm (50th centile), and head circumference was
34 cm (25-50th centile). The Apgar score was 9/9. Since
the birth, the child has been subjected to a series of
medical tests that revealed a complex clinical picture,
such as a brain ultrasound that showed the presence of
a slightly wider left ventricle. Furthermore, the presence
of further forward anus relative to the sphincter floor
was observed, so she was subsequently subjected to elec-
tro stimulation and submitted to surgery for the removal
of vegetation skin. At 30 days visit, a cranial ultrasound
showed a slightly dilated left ventricle, while there were
not cardiologic alterations or skeletal anomalies. A brain
MRI (Magnetic Resonance Imaging) confirm the pres-
ence of a wider left ventricle. Standard karyotype was
normal, as well as X-Fragile test. The neuropsychiatric
evaluation performed at the age of 4.7 years showed an
I.Q. of 89 (Stanfod Binet scale) and a mental age of
3 years and 10 months. At last clinical evaluation, per-
formed when she was 10 years old, the patient showed
facial dysmorphisms such as prominent mandible and
enlarged nasal root (Fig. 1), in association with mild
hypotonia, a hint of curvature of the trunk; a compre-
hensive neuropsychiatric evaluation has also been per-
formed. The girl showed mild ID, with a greater
operating capacity of verbal thought than visual-motor
thought. If properly stimulated, the patient offers the
best overall performance; she showed also graphomotor
delay, handling and grip difficulties. Regarding the
affective and relational behavior, the child was intro-
verted and showed attention deficit. About the commu-
nication and language area, the child showed speech
delay (dyslexia). Finally, audiological tests showed nor-
mal hearing, and eye exams showed exotropia.
Results
SNP-array analysis of the patient revealed a heterozy-
gous deletion involving chromosome 19p13.3. The de-
leted region was 710 Kb in size and covered by 159 SNP
array probes. The proximal breakpoint (telomeric) was
located between the last present probe CN_780351
(1,118,914 bp) and the first deleted probe SNP_A-
8630732 (1,120,329 bp), while the distal breakpoint
(centromeric) was located between the last deleted probe
CN_782662 (1,829,934 bp) and the first present probe
SNP_A-1937744 (1,837,061 bp) (USCS Genome Browser
build February 2009 hg19). Consequently, the maximum
size of the deletion is 718 Kb while the minimum size is
710 Kb. The subsequent microarray analysis of the pa-
tient’s parents, by using the same platform, revealed nor-
mal chromosomes 19 in both of them, indicating a de
novo deletion in the child (Fig. 2a). No additional rare
CNVs were detected in her genome.
Fig. 1 Facial phenotypes (frontal and lateral view) of the patient described in detail in the text
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According to the International System for Human
Cytogenetic Nomenclature (ISCN 2013), the molecular
karyotype of the patient was arr[hg19]19p13.3(1,118,
914x2,1,120,328-1,829,934x1,1,837,061x2)dn. This re-
arrangement was not reported as a benign CNV in the
Database of Genomic Variants (http://projects.tcag.ca/
variation/) and includes 27 genes and a miRNA. The de-
letion in the patient was confirmed by a second experi-
ment using a lower resolution array (Cytoscan 750 K
Array, Affymetrix, Santa Clara, CA). The deleted region
was 645 Kb in size (slightly smaller than the one
identified by using the SNP 6.0 array, due to the lower
resolution of the assay) and covered by 125 SNP array
probes. The first deleted probe was at 1,170,883 bp
(C-3XHQX), while the last deleted probe was at
1,816,237 bp (C-6ADPS) (USCS Genome Browser
build February 2009 hg19).
Discussion
Interstitial microdeletions of chromosome 19p13.3 are
rarely described. We report on a 10-year-old girl affected
by ID, language and behavioral delay, attention deficit,
facial dysmorphisms and eye anomalies in addition to
hypotonia and MCAs carriers of a de novo 19p13.3
interstitial microdeletion, 0.71 Mb in size, identified by
SNP-array analysis. To date, only three other cases with
overlapping rearrangement, similar in size and chromo-
somal position, have been reported in medical literature.
Clinical manifestation and molecular data of our patient
and previous cases with 19p13.3 microdeletion are listed
in Table 1 and showed in Fig. 2b.
In 2005, Archer et al. [4] described a patient, carrier of
a 0.15 Mb microdeletion on chromosome 19p13.3, af-
fected by learning difficulties/ID, dyspraxia, hypotonia,
cleft palate, unusual facial appearance, sensorineural
deafness, congenital heart defect, a prominent lateral
ventricle, seizure and immune deficiencies. In this case,
the authors suggested the haploinsufficiency of EFNA2
as possible cause for the phenotypes observed. This
patient share some clinical features with our (ID, hypo-
tonia, and cerebral anomalies).
Later, Peddibhota and colleagues [2] described eight
cases of 19p13.3 microdeletion, one of which partially
overlapped with our case. The clinical manifestations of
this patient, a 3-years-old girl, was characterized by de-
velopmental delay (DD), moderate ventriculomegaly,
Fig. 2 a Microarray-based copy number analysis performed with the Affymetrix Genome Wide Human SNP 6.0 array and visualized using the Affy-
metrix Genotyping Console Browser. Copy number state of each probe is drawn along chromosome 19 from 0 to 7,000,000 bp. The upper panel
represents the copy number state of the proband, the middle panel the father and the lower panel the mother. Values of Y-axis indicate the in-
ferred copy number according to probe intensities. Red bar is the deleted region identified in the patient. b Localization of overlapping deletions
identified in our patient and in patients already described in literature
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sub-optimal weight gain, joint laxity, right-sided ptosis,
strabismus, hiatal hernia, small umbilical hernia, hydro-
cephalus, broad forehead, widely spaced deeply set eyes,
midface retrusion, asymmetric ears, pointy chin, hypo-
tonia, delayed speech and motor development. In this
case, none of the candidate genes suggested by the au-
thors as responsible for the onset of the phenotype
(ELANE, MED16 and ARID3A) are included in the
chromosomal region deleted in our patient, even if some
clinical features are common, such as DD/ID, hypotonia,
delayed speech and motor development, ventricular
anomalies.
More recently, Kuroda et al. [5] described a 12 years old
girl carriers of a 19p13.3 microdeletion, 0.61 Mb in size
detected by array Comparative Genomic Hybridization
(aCGH), affected by Peutz Jeghers syndrome (PJS). In
addition, the patient showed ID (I.Q. 46), hypotonia, nail
pigmentation, umbilical hernia, bilateral inguinal hernias,
scoliosis, myopia, conductive deafness secondary to mid-
dle ear disease, and distinctive facial features (long face,
pointed chin, broad eyebroes, thin lip vermillion, smooth
philtrum, long hanging columella and malformed ears).
The authors identified STK11 gene as responsible for PJS
features, and suggested two other genes, ARID3A and
PTBP1, as responsible for the ID. The patient described
by Kuroda and colleagues share some clinical features
with our patient, such as hypotonia, ID and facial dys-
morphisms, but candidate genes are not shared between
them, with the exception of STK11.
Finally, in DECIPHER we found patient 253691, af-
fected by abnormality of the face and intellectual disabil-
ities, thus similar to the phenotypes observed in our
patient. Even in this case the deleted region did not en-
compass STK11, but other genes including APC2, PLK5
Table 1 Clinical manifestation and molecular data of our patient and previous cases with 19p13.3 microdeletion
Archer et al. Peddibhotla et al., Patient 8 Kuroda et al. DECIPHER 253691 Present case
Age at diagnosis (years) 16 3 12 Unknow 10
Sex Male Female Female Male Female
Coordinates of 19p13.3
microdeletion (hg19)
1,152,413–1,302,309 bp 785,691–1,444,289 bp 686,663–1,297,499 bp 1,272,198–2,138,731Bp 1,120,328–
1,829,934 bp




















































































































Ventricular anomalies + + - +
DD developmental delay, ID intellectual disability, bp base pairs, + feature present, − feature absent N.R. not reported
Palumbo et al. Molecular Cytogenetics  (2016) 9:40 Page 4 of 7
and MBD3. Respect to the three cases reported and dis-
cussed above, our patient shows behavioral delay and
marked attention deficit which may be added into the
clinical spectrum associated with the 19p13.3 microdele-
tion. Obviously more patient are needed to delineate the
full spectrum of phenotypes due to the 19p13.3
microdeletion.
From a molecular point of view, it is interestingly to
note that while previous reports describe patients
carriers of a 19p13.3 microdeletion involving a chromo-
somal region partially overlapping with the microdele-
tion identified by us, our case is the first one to date
reported in which the deletion span downstream respect
other reported deletions, involving genes which are new
candidates for the clinical manifestations. In detail, the
19p13.3 microdeletion described here encompass 27
genes (SBNO2, STK11, C19orf26, ATP5D, MIDN,
CIRBP-AS1, CIRBP, C19orf24, EFNA2, MUM1, NDUFS7,
GAMT, DAZAP1, RPS15, APC2, C19orf25, PCSK4,
REEP6, ADAMTSL5, PLK5, MEX3D, MBD3, UQCR11,
TCF3, ONECUT3, ATP8B3, REXO1) and a miRNA
(MIR1909), partially overlap with those previously re-
ported (from SBNO2 to RPS15 genes) and extends to-
wards the proximal (centromeric) ends for additional
386 Kb (from 1,444,289 to 1,829,934 bp). This additional
chromosomal region includes 13 genes (from APC2 to
REX01), some of which could be involved in the ob-
served clinical phenotype.
Between the genes located inside the deleted 19p13.3
region shared by all reported patients, we suggest as
candidates for the observed phenotypes STK11, MIDN
and EFNA2A.
STK11 encodes a member of the serine/threonine
kinase family, regulates cell polarity and functions as
a tumor suppressor, controls the activity of AMP-
activated protein kinase (AMPK) family members,
thereby playing a role in a wide range of biological
processes such as cell metabolism, cell polarity, apop-
tosis, cortical neurons polarization, axon initiation
and specification, DNA damage response [6]. Diseases
associated with STK11 include testicular tumor, som-
atic, and intussusception [6]. Because of its involve-
ment in cortical neuronal processes, we can suppose
that haploinsufficiency of STK11 could be associated
to the neurobehavioral phenotype documented in our
patient; furthermore, it could be involved in the de-
velopment of the skin vegetation observed in our pa-
tient. Also, deletions and point mutations of STK11
are the major causes of PJS [7]. Although our patient
did not show any features of this condition at the
time of clinical evaluation, we cannot exclude that
she will manifest later the clinical traits of this syn-
drome. Thus, we suggest a clinically surveillance for
the PJS.
MIDN (midnolin) is a gene potentially involved in
regulation of genes related to neurogenesis in the nucle-
olus [8], was already reported in a study aimed to iden-
tify novel autism related genes [6], thus it could
contribute to the onset of DD/ID.
EFNA2 (ephrin-A2) encodes for a member of the
ephrin family. The EPH and EPH-related receptors com-
prise the largest subfamily of receptor protein-tyrosine
kinases which have been implicated in mediating devel-
opmental events, particularly in the nervous system [9].
Since the functional evidences and its expression profile,
in agreement with Archer and colleagues [4], we con-
sider this gene as a possible candidate for the ID de-
scribed in our patient. In addition, functional studies
demonstrated the high level of expression of this gene
also during eye and retina development [10], therefore it
is reasonable to assume that EFNA2 can be involved in
the onset of eye anomalies observed. Even if some au-
thors suggested that the haploinsufficiency of these two
genes (EFNA2 and MIDN) did not impact on the pheno-
type [3], their involvement cannot be excluded, also be-
cause they have been already described as associated to
clinical conditions [11].
Between the 13 genes located inside the chromosomal
region deleted only in our patient (from 1,444,289 to
1,829,934 bp), some deserve special attention. According
to their biological functions and their expression pro-
files, APC2, PLK5 and MBD3 may have contributed to
the neurodevelopmental and behavioral phenotypes ob-
served in our patient.
The first one, APC2 (adenomatosis polyposis coli 2),
also called APCL, is primary expressed in central ner-
vous system, preferentially in post-mitotic neurons
throughout development, and it is involved in brain de-
velopment through the regulation of neuronal migration
and axon guidance [12]. APC2 protein could bind to
beta-catenin and deplete the intracellular beta-catenin
pool, suggesting that APC2 is involved in the regulation
of neuronal function in association to beta-catenin [13].
Furthermore, it was already associated to human genetic
neurological disorder [14] and Apc2-deficient mice
(Apc2−/−) exhibited impaired learning and memory
abilities along with abnormal head shape [15]. Thus,
since these functional and clinical evidences, APC2
seems to be a good functional candidate gene for the
onset of neurodevelopmental phenotype observed in
our patient.
PLK5 (Polo-like kinases 5) is a member of a protein
family characterized by the presence of a specific do-
main, known as the polo box (PDB), involved in protein-
protein interactions. Plk1 to Plk4 are involved in centro-
some biology as well as the regulation of mitosis, cyto-
kinesis and cell cycle checkpoints in response to
genotoxic stress [16]. On the contrary, Plk5 does not
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seems involved in these mechanisms, because is mostly
expressed in the brain of both mice and humans, and it
modulates the formation of neuritic processes upon
stimulation of the brain-derived neurotrophic factor
(BDNF)/nerve growth factor (NGF)-Ras pathway in neu-
rons [17]. Due to its involvement in neuronal processes,
its contribute to the clinical manifestation in our patient
cannot be excluded. Finally, a gene that may be involved
in the onset of cognitive and behavioral phenotypes ob-
served in our patient is MBD3 (methyl-CpG binding do-
main protein 3). This gene belongs to a family of nuclear
proteins which are characterized by the presence of a
methyl-CpG binding domain (MBD). The encoded
protein is a subunit of the NuRD, a multisubunit com-
plex containing nucleosome remodeling and histone
deacetylase activities. Unlike the other family members,
the encoded protein is not capable of binding to methyl-
ated DNA. The protein mediates the association of
metastasis-associated protein 2 with the core histone
deacetylase complex. A component of the same gene
family, MBD5, has been associated to neurobehavioral
abnormalities by Camarena and colleagues [18], which
reported the evidence that disruption of Mbd5 in mice
causes neuronal functional deficits and neurobehavioral
abnormalities. Even if MBD3 has never been associated
to neurobehavioral disorders, the evidence that another
member of the same gene family cause a similar clinical
phenotype may be suggestive of its contribution in the
onset of the observed traits.
Conclusion
In conclusion, we hypothesize that 19p13.3 microdele-
tions are responsible of a wide spectrum of phenotype
including ID, MCAs and dysmorphic features. Our pa-
tient has showed a microdeletion that overlaps with the
deletion region reported in several previous cases and
extends 386 Kb downstream. Phenotype comparison of
these cases suggests that deletion of the APC2, PLK5
and MBD3 genes may have contributed to behavioral
delay and marked attention deficit observed in our case.
Obviously more cases, carriers of deletions encompass-
ing candidate genes proposed in this paper, are needed
to corroborate our hypothesis and to confirm their in-
volvement in the observed traits.
Methods
SNP array analysis
Blood was obtained from the proband and his parents
after signed informed consent. The study was designed
to perform parental and proband samples concurrently
on three individual chips. Genomic DNA was isolated
from peripheral blood lymphocytes of the patient and
the parents by using BioRobot EZ1 (Quiagen, Solna,
Sweden). DNA concentration and purity were determined
with a ND-1000 Spectrophotometer (NanoDrop Tech-
nologies, Berlin, Germany) while SNP-array analysis was
performed by using Genome Wide Human SNP 6.0 Array
(Affymetrix, Santa Clara, CA). This array has, on average,
an inter-marker distance of 700 bp and makes possible an
excellent assessment of possible breakpoints of deletions
to assess copy gains or losses. The SNP 6.0 assay was per-
formed according to the manufacturer's protocol, starting
with 500 ng of DNA. Briefly: total genomic DNA was
digested with restriction enzymes (NspI and StyI), ligated
to appropriate adapters for the enzymes, and subjected to
PCR amplification using a single primer. After digestion
with DNase I, the PCR products were labeled with a bio-
tinylated nucleotide analog using terminal deoxynucleoti-
dyl transferase and hybridized to the microarray.
Hybridization was carried out in the Affymetrix
Hybridization Owen 450 while subsequent washing and
staining steps were performed using the Fluidic Station
450 and finally the array was scanned with the GeneChip
Scanner 3000 7G using Command Console Software
(Affymetrix, Santa Clara, CA, USA). Analysis was per-
formed using Genotyping Console Software 4.1 (Affyme-
trix, Santa Clara, CA, USA) and Birdseed v2-algorithm.
Samples were normalized against 270 International Hap-
Map samples while an additional 80 in-house control
samples, which were hybridized in our facility, were used
to decrease technical variation. For the copy number ana-
lysis, we used regional GC correction and required 50
markers to be found within the changed region and the
size of the region to be at least 100 kb. The amplified and/
or deleted regions were detected using a standard Hidden
Markov Model (HMM) method. Genotyping Console
Browser (Affymetrix, Santa Clara, CA, USA) was used to
illustrate changes detected while the University of Califor-
nia Santa Cruz (UCSC) Genome Browser (http://geno-
me.ucsc.edu/cgi-bin/hgGateway), assembly GRCh37, was
used to map the genomic coordinates and find the genes
within the copy number altered region.
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